LncRNA PWRN2 stimulates the proliferation and migration in papillary thyroid carcinoma through the miR-325/DDX5 axis

被引:7
作者
Xin, C. -H. [1 ]
Li, Z. [2 ]
机构
[1] Fourth Peoples Hosp Shenyang, Dept Endocrinol & Metab, Shenyang, Peoples R China
[2] Liaoning Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Internal Med Cardiovasc, Shenyang, Peoples R China
关键词
Papillary thyroid carcinoma; PWRN2; MiR-325; DDX5; Proliferation; Migration; LONG NONCODING RNA; CANCER; PROTEIN;
D O I
10.26355/eurrev_202010_23216
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: The objective of this study was to illustrate the role of long non-coding RNA (lncRNA) PWRN2 in the development of papillary thyroid carcinoma (PTC) and the potential mechanism. PATIENTS AND METHODS: Expression levels of PWRN2. miR-325 and DDX5 in 32 PTC tissues and paired normal ones were detected. The interaction in the PWRN2/miR-325/DDX5 axis was assessed by Luciferase assay. At last, the roles of the PWRN2/miR-325/DDX5 axis in regulating proliferative and migratory potentials in PTC were examined. RESULTS: It was found that PWRN2 was upregulated and miR-325 was downregulated in PTC tissues and cell lines, MiR-325 level was negatively correlated with PWRN2 level in PTC samples, and the overexpression of PWRN2 stimulated proliferative and migratory potentials in PTC cells, which were partially abolished by overexpression of miR-325. In addition, DDX5 was the target gene binding to miR-325, and its level was negatively regulated by miR325. Moreover, Luciferase assay and rescue experiments confirmed that the PWRN2/miR-325/DDX5 axis aggravated the development of PTC. CONCLUSIONS: LncRNA PWRN2 stimulates proliferative and migratory potentials in PTC through sponging miR-325 to upregulate DDX5.
引用
收藏
页码:10022 / 10027
页数:6
相关论文
共 24 条
  • [1] Increasing Incidence of Thyroid Cancer in the Commonwealth of Pennsylvania
    Bann, Darrin V.
    Goyal, Neerav
    Camacho, Fabian
    Goldenberg, David
    [J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2014, 140 (12) : 1149 - 1156
  • [2] Annual report on status of cancer in China, 2011
    Chen, Wanqing
    Zheng, Rongshou
    Zeng, Hongmei
    Zhang, Siwei
    He, Jie
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2015, 27 (01) : 2 - 12
  • [3] A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells
    Fan, Min
    Li, Xinying
    Jiang, Wei
    Huang, Yun
    Li, Jingdong
    Wang, Zhiming
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (04) : 1143 - 1146
  • [4] Hereditary and familial thyroid tumours
    Guilmette, Julie
    Nose, Vania
    [J]. HISTOPATHOLOGY, 2018, 72 (01) : 70 - 81
  • [5] MALAT1- a paradigm for long noncoding RNA function in cancer
    Gutschner, Tony
    Haemmerle, Monika
    Diederichs, Sven
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2013, 91 (07): : 791 - 801
  • [6] DEAD-box protein p68 is regulated by β-catenin/transcription factor 4 to maintain a positive feedback loop in control of breast cancer progression
    Guturi, Kiran Kumar Naidu
    Sarkar, Moumita
    Bhowmik, Arijit
    Das, Nilanjana
    Ghosh, Mrinal Kanti
    [J]. BREAST CANCER RESEARCH, 2014, 16 (06):
  • [7] Construction and analysis of a lncRNA (PWRN2)-mediated ceRNA network reveal its potential roles in oocyte nuclear maturation of patients with PCOS
    Huang, Xin
    Pan, Jiaping
    Wu, Bi
    Teng, Xiaoming
    [J]. REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2018, 16
  • [8] SV40 LARGE T-SHARES AN ANTIGENIC DETERMINANT WITH A CELLULAR PROTEIN OF MOLECULAR-WEIGHT 68,000
    LANE, DP
    HOEFFLER, WK
    [J]. NATURE, 1980, 288 (5787) : 167 - 170
  • [9] LncRNA-ATB: An indispensable cancer-related long noncoding RNA
    Li, Jinglin
    Li, Zhenglong
    Zheng, Wangyang
    Li, Xinheng
    Wang, Zhidong
    Cui, Yunfu
    Jiang, Xingming
    [J]. CELL PROLIFERATION, 2017, 50 (06)
  • [10] Competitive endogenous RNA network: potential implication for systemic lupus erythematosus
    Li, Lian-Ju
    Zhao, Wei
    Tao, Sha-Sha
    Leng, Rui-Xue
    Fan, Yin-Guang
    Pan, Hai-Feng
    Ye, Dong-Qing
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (06) : 639 - 648